Loading clinical trials...
Loading clinical trials...
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
Conditions
Interventions
Migalastat HCl 150 mg
Locations
8
United States
Clinical Study Site
Tampa, Florida, United States
Clinical Study Site
Atlanta, Georgia, United States
Clinical Study Site
Minneapolis, Minnesota, United States
Clinical Study Site
Columbia, Missouri, United States
Clinical Study Site
Cincinnati, Ohio, United States
Clinical Study Site
Pittsburgh, Pennsylvania, United States
Start Date
September 27, 2018
Primary Completion Date
February 2, 2021
Completion Date
February 6, 2021
Last Updated
November 30, 2021
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Amicus Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions